---
title: "HCA Healthcare Updates Q2 Results and 2026 Outlook"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292737822.md"
description: "HCA Healthcare reported Q2 2026 revenue of $20.23 billion and net income of $1.70 billion, driven by higher admissions but offset by a payer mix shift and surgery declines. The company revised its full-year guidance lower due to reimbursement headwinds. Analysts maintain a 'Buy' rating with a $475 target, while TipRanks' AI suggests a 'Neutral' stance citing strong profitability balanced against balance-sheet risks."
datetime: "2026-07-15T08:07:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292737822.md)
  - [en](https://longbridge.com/en/news/292737822.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292737822.md)
---

# HCA Healthcare Updates Q2 Results and 2026 Outlook

HCA Healthcare ( (HCA) ) has provided an update.

On July 14, 2026, HCA Healthcare reported preliminary second-quarter 2026 results showing revenue of about $20.23 billion, up from $18.61 billion a year earlier, and net income of roughly $1.70 billion, or $7.62 per diluted share. Adjusted EBITDA is expected at about $4.03 billion, supported by higher admissions and emergency room visits but tempered by declines in inpatient and outpatient surgeries.

Management disclosed a significant payer mix shift tied to rising uninsured volumes after coverage losses on health insurance exchanges, estimating a roughly $400 million drag on second-quarter income before taxes. At the same time, HCA recorded about $400 million in incremental net benefit from Medicaid Supplemental Payment Programs, mainly in Florida, and revised its full-year 2026 guidance slightly lower for net income, Adjusted EBITDA and EPS while modestly narrowing its revenue range, signaling both operational resilience and ongoing reimbursement and policy headwinds for investors and other stakeholders.

The most recent analyst rating on (HCA) stock is a Buy  
with a $475.00 price target.  
To see the full list of analyst forecasts on HCA Healthcare stock,  
see the HCA Stock Forecast page.

**Spark’s Take on HCA Stock**

According to Spark, TipRanks’ AI Analyst, HCA is a Neutral.

The score reflects strong operating profitability and cash generation but is held back by elevated balance-sheet risk (negative equity) and weak technical momentum (below key moving averages with negative MACD). Valuation is reasonable on earnings but offers limited dividend support, while the earnings call was constructive on guidance and cash flow despite meaningful payer and volume headwinds.

To see Spark’s full report on HCA stock,  
click here.

**More about HCA Healthcare**

HCA Healthcare, Inc. is a large U.S. hospital and healthcare services operator based in Nashville, running extensive networks of acute care hospitals and related facilities. The company focuses on inpatient and outpatient services, emergency care and surgical procedures across multiple states, with its performance closely tied to payer mix, public health policy and reimbursement programs.

**Average Trading Volume:** 1,588,794

**Technical Sentiment Signal:** Hold

**Current Market Cap:** $86.68B

Find detailed analytics on HCA stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [HCA.US](https://longbridge.com/en/quote/HCA.US.md)

## Related News & Research

- [HCA Healthcare Posts Solid Q2 2026 Results, Trims Outlook](https://longbridge.com/en/news/293756146.md)
- [HCA Healthcare Trims FY26 EPS Outlook - Update](https://longbridge.com/en/news/293753468.md)
- [HCA: Revenue up 8.7% in Q2 2026, but payer mix shifts and lower surgeries pressured margins](https://longbridge.com/en/news/293750898.md)
- [HCA Healthcare declares $0.78 dividend](https://longbridge.com/en/news/293755838.md)
- [HCA Healthcare Q2 revenue rises on Medicaid programs; narrows outlook](https://longbridge.com/en/news/293751579.md)